These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 26724654

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F.
    Eur Radiol; 2018 Sep 26; 28(9):3611-3620. PubMed ID: 29633000
    [Abstract] [Full Text] [Related]

  • 8. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014 Sep 26; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 9. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.
    Cardiovasc Intervent Radiol; 2018 Mar 26; 41(3):433-442. PubMed ID: 29086058
    [Abstract] [Full Text] [Related]

  • 10. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr 26; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 11. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V.
    Liver Transpl; 2016 Nov 26; 22(11):1491-1500. PubMed ID: 27543821
    [Abstract] [Full Text] [Related]

  • 12. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R.
    Hepatology; 2013 Nov 26; 58(5):1655-66. PubMed ID: 23703789
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Nov 26; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M.
    Acta Radiol; 2018 Jul 26; 59(7):765-772. PubMed ID: 28927298
    [Abstract] [Full Text] [Related]

  • 15. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G.
    Int J Cancer; 2017 Jan 15; 140(2):390-399. PubMed ID: 27681592
    [Abstract] [Full Text] [Related]

  • 20. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T.
    Int J Cancer; 2017 Sep 01; 141(5):1011-1017. PubMed ID: 28555943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.